论文部分内容阅读
婴儿严重联合免疫缺陷病(SCID)仅能用HLA相同的供髓者作骨髓移植治愈,近来,五肽胸腺生成素(TP-5)已合成。本文评价应用TP-5治疗原发性免疫缺陷患者的安全性和疗效,26例患者(年龄3个月～24岁)均有原发性免疫缺陷病的临床和免疫
Severe combined immunodeficiency disease (SCID) in infants can only be cured by bone marrow transplantation with the same HLA donor, and recently pentapeptide thymopoietin (TP-5) has been synthesized. This article evaluates the safety and efficacy of TP-5 in the treatment of patients with idiopathic immunodeficiency. All 26 patients (age range, 3 months to 24 years) have clinical and immunologic